Cardiac autonomic neuropathy in diabetes predicts cardiovascular events, and improving autonomic balance via lifestyle modifications and agents like SGLT2 inhibitors may reduce early mortality.
Does improving autonomic nervous system balance reduce cardiovascular events, cardiac failure, and early mortality in the diabetic population?
Cardiac autonomic neuropathy is a key predictor of cardiometabolic events in diabetes, highlighting the need for targeted lifestyle and pharmacological interventions to restore autonomic balance.
Autonomic nervous system (ANS) imbalance manifesting as cardiac autonomic neuropathy in the diabetic population is an important predictor of cardiovascular events. Symptoms and signs of ANS dysfunction, such as resting heart rate elevations, diminished blood pressure responses to standing, and altered time and frequency domain measures of heart rate variability in response to deep breathing, standing, and the Valsalva maneuver, should be elicited from all patients with diabetes and prediabetes. With the recognition of the presence of ANS imbalance or for its prevention, a rigorous regime should be implemented with lifestyle modification, physical activity, and cautious use of medications that lower blood glucose. Rather than intensifying diabetes control, a regimen tailored to the individual risk of autonomic imbalance should be implemented. New agents that may improve autonomic function, such as SGLT2 inhibitors, should be considered and the use of incretins monitored. One of the central mechanisms of dysfunction is disturbance of the hypothalamic cardiac clock, a consequence of dopamine deficiency that leads to sympathetic dominance, insulin resistance, and features of the metabolic syndrome. An improvement in ANS balance may be critical to reducing cardiovascular events, cardiac failure, and early mortality in the diabetic population.
Vinik et al. (Mon,) conducted a review in Diabetes and prediabetes. Cardiac autonomic neuropathy was evaluated. Cardiac autonomic neuropathy in diabetes predicts cardiovascular events, and improving autonomic balance via lifestyle modifications and agents like SGLT2 inhibitors may reduce early mortality.